Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Key Points

• Royal Bank of Canada raised its price target on Definium from $20 to $36 and maintained an "outperform" rating, implying roughly a 108% upside from the current share price.
• Analysts have a consensus Buy rating with an average price target of $32.11 after multiple upgrades; the stock trades around $17.29 with a $1.70 billion market cap and analysts expect negative EPS this year.
• Definium is a clinical-stage biopharma (formerly Mind Medicine) with lead programs MM120 in Phase 3 and DT402 in Phase 2a, and insiders sold shares recently, leaving insiders owning about 2.26% of the stock.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) had its price target raised by equities research analysts at Royal Bank Of Canada from $20.00 to $36.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Royal Bank Of Canada's target price indicates a potential upside of 108.21% from the stock's current price.

Several other equities analysts have also recently issued reports on DFTX. Canaccord Genuity Group boosted their price objective on Definium Therapeutics from $16.00 to $25.00 and gave the company a "buy" rating in a report on Friday, November 7th. Lifesci Capital raised Definium Therapeutics to a "strong-buy" rating in a report on Tuesday, October 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Definium Therapeutics in a report on Wednesday, October 8th. Jones Trading assumed coverage on shares of Definium Therapeutics in a research note on Tuesday, December 23rd. They set a "buy" rating and a $61.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a "buy" rating on shares of Definium Therapeutics in a report on Monday, January 5th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $32.11.

Definium Therapeutics Stock Performance

NASDAQ DFTX traded up $0.32 on Friday, hitting $17.29. 223,405 shares of the company's stock traded hands, compared to its average volume of 2,295,601. The firm's 50-day moving average price is $13.04 and its two-hundred day moving average price is $11.35. The firm has a market capitalization of $1.70 billion, a PE ratio of -8.48 and a beta of 2.57. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31. Definium Therapeutics has a 1-year low of $4.70 and a 1-year high of $18.12.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.26). As a group, analysts expect that Definium Therapeutics will post -1.35 EPS for the current year.

Insider Activity

In related news, insider Mark Sullivan sold 11,276 shares of the firm's stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the transaction, the insider directly owned 282,576 shares of the company's stock, valued at approximately $3,715,874.40. This trade represents a 3.84% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert Barrow sold 25,791 shares of the business's stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the sale, the chief executive officer owned 778,477 shares of the company's stock, valued at approximately $10,236,972.55. This trade represents a 3.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 42,667 shares of company stock worth $561,071 in the last quarter. Corporate insiders own 2.26% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP grew its holdings in shares of Definium Therapeutics by 31.9% during the 2nd quarter. Marshall Wace LLP now owns 3,421,224 shares of the company's stock worth $22,204,000 after purchasing an additional 828,067 shares during the period. Commodore Capital LP lifted its position in Definium Therapeutics by 10.5% in the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company's stock valued at $32,450,000 after buying an additional 475,000 shares during the last quarter. Orbimed Advisors LLC purchased a new position in Definium Therapeutics during the third quarter worth about $4,337,000. Rosalind Advisors Inc. increased its position in shares of Definium Therapeutics by 78.6% during the third quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company's stock valued at $8,842,000 after acquiring an additional 330,000 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in shares of Definium Therapeutics by 424.9% during the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company's stock valued at $3,495,000 after acquiring an additional 239,965 shares during the last quarter. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.